<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235273</url>
  </required_header>
  <id_info>
    <org_study_id>TOSCAproject</org_study_id>
    <nct_id>NCT01235273</nct_id>
  </id_info>
  <brief_title>Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.</brief_title>
  <acronym>TOSCA2</acronym>
  <official_title>Phase 2 Study of Growth Hormone Administration in Patients With Chronic Heart Failure and Low IGF-1 Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine whether treatment of the low IGF-1 syndrome in
      patients with CHF is able to modify some functional parameters, recognized as valid surrogate
      end-points of CHF progression.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    insufficient enrollment
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>increase of peak VO2 consumption by at least 2.5 ml/kg/min during maximal physical exercise test.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>GH replacement therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>growth hormone administration</description>
    <arm_group_label>GH replacement therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>standard placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients of either sex affected by CHF NYHA class II-III, secondary to ischemic or
             idiopathic dilated cardiomyopathy

          -  age range 30-80 years

          -  stable medications for at least two months prior to randomization, including ACE
             inhibitors or AT1 antagonists and beta-blockers (unless untolerated).

          -  LV ejection fraction 40% or less

          -  Peak VO2 consumption during a CPET â‰¤ 16 ml/kg/min.

          -  LV end-diastolic dimension 55 mm or more

          -  low IGF-1 levels and a satisfactory response to an IGF-1 generation test

          -  informed consent

        Exclusion Criteria:

          -  haemodynamic clinically significant primary valvular disease or significant congenital
             heart disease

          -  acute pericarditis/myocarditis

          -  inability to perform a bicycle exercise test

          -  Poorly controlled diabetes mellitus (HbA1c &gt;8.5)

          -  active proliferative or severe non-proliferative diabetic retinopathy

          -  active and/or history of malignancy

          -  evidence of progression or recurrence of an underlying intracranial tumor

          -  unstable angina or recent myocardial infarction (less than 5 months)

          -  severe liver disease

          -  serum creatinine levels &gt;2.5 mg/dl

          -  Inability to cooperate or administer the study drug

          -  Patients participating in any other clinical study, within 30 days prior to screening
             visit and/or during this particular study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Antonio Cittadini</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Antonio Cittadini</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

